Clinical Trials Logo

Progression clinical trials

View clinical trials related to Progression.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04844437 Active, not recruiting - Clinical trials for Ultrasound Therapy; Complications

Intrapartum Translabial Ultrasonography Reliability

ITUSR
Start date: February 20, 2021
Phase:
Study type: Observational [Patient Registry]

In a present study vaginal examination of the fetal head station is compared with transperineal ultrasonography evaluation of fetal head station and the ability of ultrasonography evaluation in predicting the time and mode of delivery will be investigated.

NCT ID: NCT04682457 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 1

Defining the Decline in Endogenous Insulin Secretion in Type 1 Diabetes Diagnosed After 30 Years of Age.

DROPLeT
Start date: November 1, 2019
Phase:
Study type: Observational

The study aims is to find out if people with type 1 diabetes diagnosed in later life (after age 30) have the same rapid loss of insulin secretion (measured using C-peptide) that occurs in younger adults with type 1 diabetes. The investigators will recruit 135 participants aged over 30 years with a clinical diagnosis of type 1 diabetes and diabetes duration ≤100 days. The investigators will also recruit a comparison group of 61 participants aged 18-30 with a clinical diagnosis of type 1 diabetes and diabetes duration ≤100 days. C-peptide will be measured during mixed meal tolerance tests (MMTT) performed at baseline, 6 months and a year. This study also aims to test a new more practical way of monitoring insulin secretion at home using a finger prick 'blood spot' rather than time consuming tests in a hospital. Finger-prick C-peptide samples will be collected after the MMTT and by the participants at home throughout the year.

NCT ID: NCT02761070 Active, not recruiting - Glioblastoma Clinical Trials

Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III

RE-GEND
Start date: July 11, 2016
Phase: Phase 3
Study type: Interventional

The aim of this Phase III study is to evaluate the superiority of dose-dense temozolomide (ddTMZ) followed by bevacizumab at ddTMZ failure for glioblastoma at first recurrence or progression, comparing to bevacizumab alone.